BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21441823)

  • 1. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients.
    Bili A; Sartorius JA; Kirchner HL; Morris SJ; Ledwich LJ; Antohe JL; Dancea S; Newman ED; Wasko MC
    J Clin Rheumatol; 2011 Apr; 17(3):115-20. PubMed ID: 21441823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy.
    Antohe JL; Bili A; Sartorius JA; Kirchner HL; Morris SJ; Dancea S; Wasko MC
    Arthritis Care Res (Hoboken); 2012 Feb; 64(2):215-21. PubMed ID: 21972198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
    Verstappen SM; van Albada-Kuipers GA; Bijlsma JW; Blaauw AA; Schenk Y; Haanen HC; Jacobs JW;
    Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.
    Wasko MC; Hubert HB; Lingala VB; Elliott JR; Luggen ME; Fries JF; Ward MM
    JAMA; 2007 Jul; 298(2):187-93. PubMed ID: 17622600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
    Solomon DH; Massarotti E; Garg R; Liu J; Canning C; Schneeweiss S
    JAMA; 2011 Jun; 305(24):2525-31. PubMed ID: 21693740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G; Pedro S; Holmqvist ME; Avery M; Wolfe F; Michaud K
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR; Haire CE; Erikson N; Drymalski W; Palmer W; Eckhoff PJ; Garwood V; Maloley P; Klassen LW; Wees S; Klein H; Moore GF
    N Engl J Med; 1996 May; 334(20):1287-91. PubMed ID: 8609945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
    Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors.
    Chakravarty EF; Michaud K; Wolfe F
    J Rheumatol; 2005 Nov; 32(11):2130-5. PubMed ID: 16265690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients.
    Sharma TS; Wasko MC; Tang X; Vedamurthy D; Yan X; Cote J; Bili A
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26727968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study.
    Peters MJ; van Halm VP; Voskuyl AE; Smulders YM; Boers M; Lems WF; Visser M; Stehouwer CD; Dekker JM; Nijpels G; Heine R; Dijkmans BA; Nurmohamed MT
    Arthritis Rheum; 2009 Nov; 61(11):1571-9. PubMed ID: 19877093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.
    Kerr G; Aujero M; Richards J; Sayles H; Davis L; Cannon G; Caplan L; Michaud K; Mikuls T
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1619-26. PubMed ID: 24692402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study.
    Davis JM; Maradit Kremers H; Crowson CS; Nicola PJ; Ballman KV; Therneau TM; Roger VL; Gabriel SE
    Arthritis Rheum; 2007 Mar; 56(3):820-30. PubMed ID: 17330254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.
    Nicola PJ; Maradit-Kremers H; Roger VL; Jacobsen SJ; Crowson CS; Ballman KV; Gabriel SE
    Arthritis Rheum; 2005 Feb; 52(2):412-20. PubMed ID: 15692992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital.
    de Thurah A; Nørgaard M; Johansen M; Stengaard-Pedersen K
    Scand J Rheumatol; 2010; 39(1):19-25. PubMed ID: 20132066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.